AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04845282 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: RDA Protein plus Resistance Training
Description: Participants will be counseled to consume the RDA level of protein (0.8g/kg/day) utilizing only dietary protein.
Study NCT06027164 — intervention group
Intervention type: DEVICE
Intervention: Portable Ultrasound System
Description: EchoNous KOSMOS
Study NCT04588038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efineptakin alfa
Description: Given via intramuscular injection
Study NCT04985123 — intervention group
Intervention type: DEVICE
Intervention: Pre-Formed Penile Silicone Block Implant
Description: Implantation of Pre-Formed Penile Silicone Block Implant
Study NCT06193460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level laser therapy
Description: photobiomodulation mode of diode laser (low-level laser therapy).
Study NCT05535465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Public health intervention
Description: additional trained mobile health workers are hired to support and supervise the activities of community health workers
Study NCT05602831 — intervention group
Intervention type: OTHER
Intervention: detect HPV and genetic variants
Description: Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline surgical tissues.
Study NCT05602831 — intervention group
Intervention type: OTHER
Intervention: detect HPV and genetic variants
Description: Serum tumor markers and ctDNA HPV and genetic variants will be detected in peripheral blood samples. HPV and genetic variants will be also detected in baseline puncture tissues.
Study NCT05516550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid
Description: Participants will receive Treamid 25 mg once a day daily during 4 weeks
Study NCT05516550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid twice a day
Description: Participants will receive Treamid 25 mg in the morning and in the evening daily during 4 weeks
Study NCT05516550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid once a day
Description: Participants will receive Treamid 50 mg in the morning daily during 4 weeks
Study NCT05516550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive Placebo in the morning and in the evening daily during 4 weeks
Study NCT03503032 — intervention group
Intervention type: PROCEDURE
Intervention: Extracardiac Fontan
Description: Extracardiac Fontan (Total cavo-pulmonary connection) will be constructed with a tube graft from the inferior vena cava to the pulmonary artery \[applied to both arms\]
Study NCT03503032 — intervention group
Intervention type: PROCEDURE
Intervention: Fontan fenestration
Description: Fontan fenestration created as a single 3 to 6mm communication between fontan channel and pulmonary venous atrium \[Fenestrated arm\]
Study NCT05172349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LV-Visio-AMTRIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit
Study NCT04684277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antidepressant treatment
Description: depression recieve antidepressant treatment
Study NCT04684277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: antidepressant treatment combined with Internet-based interventions
Description: depression recieve antidepressant treatment combined with Internet-based interventions
Study NCT05486377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: Remimazolam besylate TIVA
Study NCT04986904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi (Sleep Healthy Using the Internet)
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
Study NCT05294549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caring Contact
Description: The Caring Contact intervention is an email with messages of hope, support and resource information sent to patients post-discharge from psychiatric hospitalization.
Study NCT06498076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: injection of prophylactic norepinephrinebolus after spinal anesthesia induction. If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
Study NCT06498076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: injection of prophylactic ephedrine If hypotension at any time during surgery, administration of rescue bolus of the same vasopressor to each patient.
Study NCT01687530 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AMCA Bone Membrane.
Description: AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
Study NCT06033651 — intervention group
Intervention type: RADIATION
Intervention: x-ray
Description: A sample of blood will be taken and sent to a lab in Surrey to check for metal ions.
Study NCT06099847 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TENS Stimulation
Description: Sacral TENS device without appropriate electrical stimulation have been applied to directly the skin of sacral area.
Study NCT06099847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sacral TENS Stimulation
Description: Sacral TENS stimulation have been applied to directly the skin of sacral area.
Study NCT06268275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp block
Description: Receive 30 ml of 0.25% bupivacaine with 1% lidocaine (1:1) with adrenaline 1:200,000 infiltration for 10 minutes before skull pins application.
Study NCT06268275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Receive Intravenous esmolol 1 mg/kg bolus over 1 minute before skull pins application
Study NCT04690023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerves group (PENG) block
Description: Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided PENG block with injection 20 ml of ropivacaine 0,75%, between the anterior hip articular capsule, the ilii-psoas muscle, the ileo-pubic eminence and the antero-inferior iliac spine.
Study NCT04690023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supra-inguinal fascia-iliaca compartment block
Description: Patients scheduled for total hip arthroplasty with spinal anesthesia receive before intra-thecal injection, ultrasound-guided supra-inguinal fascia iliaca compartment block with injection over de inguinal ligament of 40 ml of ropivacaine 0,375%, between de ilio-psoas muscle and internal oblique muscle.
Study NCT04690023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,75% in PENG block
Description: 20 ml injection of ropivacaine 0,75%
Study NCT04690023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,375% in SFICB block
Description: 40 ml injection of ropivacaine 0,375%
Study NCT05831813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal-Based Cognitive Behavioural Intervention
Description: A goal-based cognitive behavioural intervention in a group format that addresses negative social cognitions and focuses on social approach processes
Study NCT06305728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 89Zr-DFO-HuMab-5B1 immunoPET
Description: Participants who choose to will undergo immunoPET before surgery.
Study NCT06305728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HP MRI
Description: Participants who choose to will undergo HP MRI before surgery.
Study NCT06305728 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Blood assay
Description: Will be drawn within 6 weeks of surgery and annually as post operative care
Study NCT04978675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 rhPSMA-7.3
Description: Given IV
Study NCT04978675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT04978675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT06176339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline Oral Tablet
Description: Pentoxifylline 400 mg extended-release oral tablets will be administered orally three times per day through the chemotherapy cycles.
Study NCT06176339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be administered orally three times per day through the time of the chemotherapy cycles.
Study NCT05061784 — intervention group
Intervention type: PROCEDURE
Intervention: Routine thymectomy, which has been performed
Description: There is no intervention
Study NCT05760053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP/EC+PD-1
Description: Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.
Study NCT04652167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCT
Description: Serum PCT concentration is quantified with an automated sandwich immunoassay ECLIA (Elecsys®, BRAHMS PCT-analyses) on Cobas e801. Calibration (BRAHMS PCT LIA assay) is performed once per reagent lot and no later than 24 h after Cobas e pack has been registered in the instrument. Quality control is performed after each calibration.
Study NCT04652167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: suPAR
Description: Serum suPAR was measured using suPARnostic© Turbilatex assay reagents (validated on Cobas© c111) protocol for Cobas© c702 and c502 applying the Multi-Pack cassettes (Roche Diagnostics, Mannheim, Germany). Calibration is performed at least once a month or in connection to a new batch of TurbiLatex reagents, after calibration a quality control is performed.
Study NCT04652167 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Standard care
Description: Standard care is the measurement of CRP (C-reactive protein) will be measured with C - reactive protein (CRP4) immunoturbidimetric assay (Tina-quant®, Roche) on Roche/Hitachi cobas© systems c701/702. Calibration is performed (Tina-quant® C - reactive protein IV) once per reagent lot and after 6 months using the same reagent lot. Quality control is required after calibration and according manufacturing instructions.
Study NCT06172881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Contact Lens
Description: A soft contact lens that will be worn only at the study visit.
Study NCT06015425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MINDD STIM+
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study NCT04089969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTA/FFRct
Description: Computed Tomography Angiogram with Fractional Flow Reserve. A Ct scan of the heart's blood vessels.
Study NCT04089969 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SOC cardiovascular evaluation
Description: Standard of care (SOC) cardiovascular evaluation i.e ECG, 2 D echocardiogram and pharmacologic stress test such as Dobutamine and Myocardial Perfusion Imaging stress test.
Study NCT06434519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole cream
Description: After application of one of the moisturizers under investigation in this study to the right side of the patient's face, x5 tape strips will be collected from the left side of a patient's face. These will provide negative controls for quantitation of metronidazole in the stratum corneum. Then, 0.5 mL of a 1% metronidazole cream will be applied to both the right and left sides of a patient's face with clean gloves to prevent cross contamination. Tapes strips x5 will subsequently be collected from the left and right sides of the face at 1 hour and 4 hour time points to assess penetrance of metronidazole through the stratum corneum.
Study NCT06434519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil moisturizer
Description: 1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
Study NCT06434519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CeraVe moisturizer
Description: 1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
Study NCT06434519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eucerin Healing Lotion moisturizer
Description: 1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
Study NCT06434519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aveeno Calm and Restore Oat Gel moisturizer
Description: 1 mL of moisturizer will be dispensed using a pre-loaded syringe applied to the right face of each patient the patient's standard practice. No moisturizer will be applied to the left side of the face to provide for negative and positive tape strip controls to assess metronidazole penetrance through the stratum corneum in the presence of the moisturizer.
Study NCT05848557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mSaada
Description: mSaada is an integrated digital platform to support patients, community health volunteers (CHVs), providers and health systems in an HPV-based cervical cancer screening strategy. mSaada is hosted on an open-source platform (Dimagi, CommCare) as a mobile health application to support patient data collection, protocol support and counseling aids. mSaada will include an education module, patient and specimen tracking, screening reminders, and messaging functionality.
Study NCT05572073 — intervention group
Intervention type: OTHER
Intervention: Natural History Study
Description: Natural History Study
Study NCT05685589 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINDful TIME
Description: The intervention will include weekly 90-minute group meetings held online through Zoom. Adolescents and parents will meet in separate groups and will learn about mindfulness-based strategies that can be used to manage and reduce stress, anxiety, and depression. They will also learn evidence-based strategies to complete daily guided mindfulness meditations using Ten Percent Happier, a commercially-available mobile app. Participants will be encouraged to meditate using the mobile app for at least 10 minutes each day during and after the 8-week intervention.
Study NCT05395910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: This is a prospective, two armed phase I trial in a 3 + 3 dose escalation evaluating the safety and tolerability of PIPAC/ePIPAC using paclitaxel in patients with peritoneal carcinomatosis.
Study NCT05784480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Checklist for evaluation of reversible causes
Description: Prehospital evaluation by checklist and diagnostic testing for reversible causes of OHCA using point-of-care blood gas analysis, saliva toxicological screen and ultrasound and post-hoc toxicological analysis of blood using mass spectrometry
Study NCT05344313 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Plus Advance
Description: as in the arm description of the intervention
Study NCT04605887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Angiotensin 1-7
Description: Ang 1-7 subcutaneously 500 mcg/kg /day
Study NCT05348213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib plus R-ICE
Description: Zanubrutinib 160mg/bid PO D1-21 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study NCT05348213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus R-ICE
Description: Decitabine 10mg/m2 IV D1-5 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study NCT05348213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide plus R-ICE
Description: Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study NCT05348213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib plus R-ICE
Description: Tofacitinib 5mg/bid PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study NCT05348213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide plus R-ICE
Description: Pomalidomide 4mg/d PO D1-10 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study NCT04605887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin 1-7
Description: Ang 1-7 subcutaneously 500 mcg/kg /day
Study NCT04950725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength RMT
Description: 2 sets of 10 breaths twice per day using the breather or 3 sets of 10 breaths, twice per day using the Breather Fit
Study NCT04950725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength RMT and nasal breathing
Description: 2 sets of 10 breaths twice per day using the Breather or 3 sets of 10 breaths twice per day using the Breather Fit. Subjects will also be asked to complete 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
Study NCT04950725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance RMT
Description: 15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit
Study NCT04950725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance RMT and nasal breathing
Description: 15 breaths twice per day using the Breather or 20 breaths twice per day using the Breather Fit at a lower intensity for a longer duration without break. Subjects will also perform 2 sets of 10 nasal breathing exercises either before or after the RMT exercise.
Study NCT04950725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dose RMT
Description: 10 breaths, 3 times per week, at an intensity of 3 to 4 out of 10 using the Breather device.
Study NCT06023277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ConvitVax
Description: ConvitVax is a personalized vaccine designed to treat women with breast cancer. The vaccine is composed of three widely commonly used components: autologous tumor cells obtained from the patient's own tumor tissue, BCG D1331, plus a low concentration of formalin.
Study NCT05727254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Agility training
Description: Multi-component (strength, balance, cognition) exercise training.
Study NCT05727254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise recommendations
Description: Participants are being given the standard recommendations how much exercise and what type older adults should do.
Study NCT05727254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise recommendations
Description: Participants are being given the standard recommendations how much exercise and what type older adults should do.
Study NCT05727254 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise diary
Description: Participants are instructed to write down their physical activity and exercises.
Study NCT05727254 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise diary
Description: Participants are instructed to write down their physical activity and exercises.
Study NCT06101433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy isoflavone
Description: the subjects in the soy isoflavone group were told to take 2 drugs per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
Study NCT06101433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the subjects in the placebo group were told to take 2 placebo tablets per day, one in the morning after the breakfast and one at night after the dinner and continue this pattern for 12 weeks.
Study NCT06243419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vein viewer
Description: The PIC region was visualized with the help of the device, and the vein to which the intervention would be applied was determined.
Study NCT06243419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: The child watched the application by wearing virtual glasses during the PIC insertion